Europe Chronic Cough Market to Grow at a CAGR of 7.3% to reach US$ 2,881.55 Million from 2020 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Chronic Cough Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Chronic Cough Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising Incidences of Chronic Cough
5.1.2 Growing Product Developments to Treat Chronic Cough

5.2 Market Opportunities

5.2.1 Aging Population is Expected to Drive Demand for Chronic Cough Treatment

5.3 Future Trends

5.3.1 Continuous Trend of Drug Development

5.4 Impact of Drivers and Restraints

6. Europe Chronic Cough Market Regional Analysis

6.1 Europe Chronic Cough Market Overview

6.2 Europe Chronic Cough Market Revenue 2017-2027 (US$ Million)

6.3 Europe Chronic Cough Market Forecast Analysis

7. Europe Chronic Cough Market Analysis – by Drug Class

7.1 Antihistamines

7.1.1 Overview
7.1.2 Antihistamines: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Corticosteroids

7.2.1 Overview
7.2.2 Corticosteroids: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Decongestants

7.3.1 Overview
7.3.2 Decongestants: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Combination Drug

7.4.1 Overview
7.4.2 Combination Drug: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Antibiotics

7.5.1 Overview
7.5.2 Antibiotics: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

7.6 Acid Blockers

7.6.1 Overview
7.6.2 Acid Blockers: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

7.7 Other Drug Class

7.7.1 Overview
7.7.2 Other Drug Class: Europe Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Chronic Cough Market Analysis – by Route of Administration

8.1 Oral

8.1.1 Overview
8.1.2 Oral: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Injections

8.2.1 Overview
8.2.2 Injections: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Inhalation

8.3.1 Overview
8.3.2 Inhalation: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Other Route of Administration

8.4.1 Overview
8.4.2 Other Route of Administration: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

9. Europe Chronic Cough Market Analysis – by Distribution Channel

9.1 Hospital Pharmacy

9.1.1 Overview
9.1.2 Other Route of Administration: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Online Pharmacy

9.2.1 Overview
9.2.2 Other Route of Administration: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Retail Pharmacy

9.3.1 Overview
9.3.2 Other Route of Administration: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10. Europe Chronic Cough Market – Europe Analysis

10.1 Europe

10.1.1 Europe Chronic Cough Market Breakdown, by Key Country, 2020 and 2027 (%)
10.1.1.1 Europe Chronic Cough Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 UK: Europe Chronic Cough Market Breakdown, by Drug Class
10.1.1.1.2 UK: Europe Chronic Cough Market Breakdown, by Route of Administration
10.1.1.1.3 UK: Europe Chronic Cough Market Breakdown, by Distribution Channel

10.1.1.2 Germany: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Germany: Europe Chronic Cough Market Breakdown, by Drug Class
10.1.1.2.2 Germany: Europe Chronic Cough Market Breakdown, by Route of Administration
10.1.1.2.3 Germany: Europe Chronic Cough Market Breakdown, by Distribution Channel

10.1.1.3 France: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 France: Europe Chronic Cough Market Breakdown, by Drug Class
10.1.1.3.2 France: Europe Chronic Cough Market Breakdown, by Route of Administration
10.1.1.3.3 France: Europe Chronic Cough Market Breakdown, by Distribution Channel

10.1.1.4 Russia: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Russia: Europe Chronic Cough Market Breakdown, by Drug Class
10.1.1.4.2 Russia: Europe Chronic Cough Market Breakdown, by Route of Administration
10.1.1.4.3 Russia: Europe Chronic Cough Market Breakdown, by Distribution Channel

10.1.1.5 Italy: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.5.1 Italy: Europe Chronic Cough Market Breakdown, by Drug Class
10.1.1.5.2 Italy: Europe Chronic Cough Market Breakdown, by Route of Administration
10.1.1.5.3 Italy: Europe Chronic Cough Market Breakdown, by Distribution Channel

10.1.1.6 Rest of Europe: Europe Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Chronic Cough Market Breakdown, by Drug Class
10.1.1.6.2 Rest of Europe: Europe Chronic Cough Market Breakdown, by Route of Administration
10.1.1.6.3 Rest of Europe: Europe Chronic Cough Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Chronic Cough Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Novartis AG

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Teva Pharmaceutical Industries Ltd

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 GlaxoSmithKline plc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Bayer AG

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Mylan N.V.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Amneal Pharmaceuticals, Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Cipla Inc.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Reckitt Benckiser Group plc.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Sun Pharmaceutical Industries Ltd

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Aurobindo Pharma Ltd

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights